{"ticker": {"uuid": "bdcbe306-d939-4347-8ef3-34215eb4545e", "symbol": "DSGN", "name": "Design Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Myotonic Dystrophy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 \u2013 DelveInsight | Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Bioscien", "summary": "The Myotonic Dystrophy market is projected to reach approximately USD 89 million in 2023 and grow at an 18.4% CAGR through 2036, driven by increased disease awareness, genetic research advancements, and a robust clinical pipeline. Several companies, including Avidity Biosciences ", "url": "https://www.barchart.com/story/news/3186311/myotonic-dystrophy-market-expected-to-experience-accelerated-growth-and-market-evolution-by-2036-delveinsight-design-therapeutics-enzerna-juvena-therapeutics-dyne-therapeutics-avidity-bioscien", "source_name": "Barchart.com", "published_at": "2026-07-08T14:10:50", "published_display": "08 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Design Therapeutics, Inc. (DSGN)", "summary": "This article examines the historical performance of investing $1,000 in Design Therapeutics, Inc. (DSGN) over various periods, showing substantial gains in the last year but losses over longer terms. It also provides a detailed overview of the company, a clinical-stage biotechnol", "url": "https://www.stocktitan.net/tools/stock-return-calculator/DSGN", "source_name": "Stock Titan", "published_at": "2026-07-04T12:40:30", "published_display": "04 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Design Therapeutics, Inc. \u2013 NASDAQ:DSGN", "summary": "This article displays the \"Price to sales forward\" financial metric for Design Therapeutics, Inc. (NASDAQ: DSGN). The content includes the company's stock symbol, market, and a brief mention of the financial data period, value, and change.", "url": "https://www.tradingview.com/symbols/NASDAQ-DSGN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T05:11:30", "published_display": "03 Jul 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Design Therapeutics, Inc. \u2013 NASDAQ:DSGN", "summary": "This page from TradingView displays financial information for Design Therapeutics, Inc. (NASDAQ: DSGN), specifically focusing on its forward price-to-earnings ratio. The content indicates that the market was closed at the time of access, with no trades occurring. The page also li", "url": "https://www.tradingview.com/symbols/NASDAQ-DSGN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T03:09:11", "published_display": "03 Jul 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics (Nasdaq:DSGN) - Stock Analysis", "summary": "This article provides a stock analysis of Design Therapeutics (DSGN), highlighting its current market performance, risk factors, and pipeline developments. The company, a clinical-stage biopharmaceutical firm focusing on genetic diseases, shows significant stock growth over the p", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dsgn/design-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-07-01T12:10:56", "published_display": "01 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Design Therapeutics stock rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQcU1JaXAwekYtT2dsbUo3blRzdUtIa0xGTGFuNzBGdXhfXzhrR3phTHZnMW1jdFNHMWtfTGJGVzA2dXhyLV9WcC11anlvX0VCZi1ZeFFrZGdheEdrV0RLdVhTbUpydjU2bWoxdzlFMlRIY3duOWRSUTlvbkIyZ2p3XzF3Q0xscm9lcWRhc2lkT0Z3OWRrWDVLa0NLYmExNko5VHJNRGIzaGhxaHZISWotODF3cUt2ZDhOdXN4dFpR?oc=5", "source_name": "Investing.com", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics begins dosing DM1 drug in phase 1 trial By Investing.com", "summary": "Design Therapeutics (NASDAQ:DSGN) has initiated patient dosing for its DT-818 drug in a Phase 1 clinical trial for adults with myotonic dystrophy type-1, leading to a 6.7% surge in its stock. The company anticipates reporting data from this trial in 2027 and continues to advance ", "url": "https://ca.investing.com/news/stock-market-news/design-therapeutics-begins-dosing-dm1-drug-in-phase-1-trial-93CH-4713737", "source_name": "Investing.com Canada", "published_at": "2026-06-30T23:10:16", "published_display": "30 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics begins DM1 trial for DT-818, aims at genetic cause", "summary": "Design Therapeutics (Nasdaq: DSGN) has initiated patient dosing for its Phase 1 multiple-ascending dose (MAD) trial of DT-818, a GeneTAC small molecule, for adults with myotonic dystrophy type-1 (DM1). DT-818 is designed to address the underlying genetic cause of DM1 by selective", "url": "https://www.stocktitan.net/news/DSGN/design-therapeutics-announces-initiation-of-patient-dosing-in-phase-uqdjp75me0ja.html", "source_name": "Stock Titan", "published_at": "2026-06-30T23:10:16", "published_display": "30 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics begins dosing DM1 drug in phase 1 trial", "summary": "Design Therapeutics (NASDAQ:DSGN) has commenced patient dosing in a Phase 1 clinical trial for DT-818, a potential treatment for myotonic dystrophy type-1 (DM1). The company's stock surged on the news, having already seen significant gains over the past year. DT-818 is designed t", "url": "https://www.investing.com/news/company-news/design-therapeutics-begins-dosing-dm1-drug-in-phase-1-trial-93CH-4767732", "source_name": "Investing.com", "published_at": "2026-06-30T12:41:11", "published_display": "30 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 79, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics stock rises on Phase 1 trial dosing start By Investing.com", "summary": "Design Therapeutics Inc. (NASDAQ:DSGN) shares rose in premarket trading after the company announced the initiation of patient dosing in its Phase 1 trial for DT-818. This GeneTAC small molecule aims to treat myotonic dystrophy type-1 (DM1) by targeting the underlying genetic caus", "url": "https://m.au.investing.com/news/stock-market-news/design-therapeutics-stock-rises-on-phase-1-trial-dosing-start-93CH-4511350?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-30T12:41:11", "published_display": "30 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1", "summary": "Design Therapeutics has initiated patient dosing for its Phase 1 multiple-ascending dose (MAD) clinical trial of DT-818, a GeneTAC\u00ae small molecule for Myotonic Dystrophy Type-1 (DM1). DT-818 is designed to address the genetic cause of DM1 by selectively reducing the transcription", "url": "https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/design-therapeutics-announces-initiation-of-patient-dosing-in-phase-1-multiple-ascending-dose-trial-of-dt-818-for-myotonic-dystrophy-type-1/2375725", "source_name": "The Manila Times", "published_at": "2026-06-30T11:41:11", "published_display": "30 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics spikes as RBC upgrades on an eventful 2026", "summary": "Design Therapeutics (NASDAQ:DSGN) saw its shares rise after RBC Capital upgraded the stock, citing upcoming catalysts and a potentially \"eventful\" 2026. The upgrade reflects optimism about the company's future prospects and clinical developments.", "url": "http://www.msn.com/en-us/money/savingandinvesting/design-therapeutics-spikes-as-rbc-upgrades-on-an-eventful-2026/ar-AA1QPGsJ?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-30T11:09:52", "published_display": "30 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics, Inc.(NasdaqGS:DSGN) added to Russell Small Cap Comp Growth Benchmark", "summary": "Design Therapeutics, Inc. (DSGN) has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion is among several recent updates for the company within the Russell indices, including additions to the Russell 2500 Growth Benchmark and Russell Microcap Growth Benchmar", "url": "https://www.marketscreener.com/news/design-therapeutics-inc-nasdaqgs-dsgn-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc8bf424", "source_name": "marketscreener.com", "published_at": "2026-06-29T21:39:45", "published_display": "29 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics, Inc.(NasdaqGS: DSGN) dropped from Russell 2000 Value Benchmark", "summary": "Design Therapeutics, Inc. (NasdaqGS: DSGN) has been removed from the Russell 2000 Value Benchmark, as announced on June 29, 2026. This news comes alongside several other Russell index adjustments for the company, including being added to the Russell Small Cap Comp Growth, Russell", "url": "https://www.marketscreener.com/news/design-therapeutics-inc-nasdaqgs-dsgn-dropped-from-russell-2000-value-benchmark-ce7f5fdfd88cf722", "source_name": "marketscreener.com", "published_at": "2026-06-29T15:39:45", "published_display": "29 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 3000E Growth Benchmark", "summary": "Design Therapeutics, Inc. (NasdaqGS: DSGN) has been added to the Russell 3000E Growth Benchmark. The company specializes in developing GeneTACT molecules\u2014small-molecule gene-targeted chimera therapeutic candidates designed for diseases caused by inherited nucleotide repeat expans", "url": "https://www.marketscreener.com/news/design-therapeutics-inc-nasdaqgs-dsgn-added-to-russell-3000e-growth-benchmark-ce7f5fdedf88f325", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:10:48", "published_display": "29 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely", "summary": "Design Therapeutics (NASDAQ:DSGN), a loss-making company, saw its share price soar by 274% over the last year. Despite an increase in cash burn to US$54 million, the company maintains a robust cash runway of 4.1 years based on its US$223 million cash reserves. Analysts believe De", "url": "https://www.sahmcapital.com/news/content/were-hopeful-that-design-therapeutics-nasdaqdsgn-will-use-its-cash-wisely-2026-06-27", "source_name": "Sahm", "published_at": "2026-06-27T10:40:21", "published_display": "27 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics, Inc. Actuals & Estimates (NASDAQ:DSGN)", "summary": "This article provides an overview of Design Therapeutics, Inc. (DSGN) stock performance, financial estimates, and analyst forecasts. It includes details on the current stock price, volatility, market capitalization, historical highs and lows, and upcoming earnings reports, along ", "url": "https://www.tradingview.com/symbols/NASDAQ-DSGN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T05:10:05", "published_display": "27 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DSGN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an outlook on Design Therapeutics, Inc. (DSGN) stock, including analyst price targets, historical performance, and financial data. Analysts predict a max estimate of $22.00 and a min estimate of $20.00 for DSGN. The company's stock has shown significant grow", "url": "https://www.tradingview.com/symbols/NASDAQ-DSGN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T08:41:54", "published_display": "26 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics Inc (DSGN) Institutional Confidence", "summary": "Design Therapeutics Inc (DSGN) has an institutional shareholding score of 5.00, ranking 132nd in the Biotechnology & Medical Research industry, with institutional shareholding at 61.89%, a decrease of 8.26% quarter-over-quarter. Steven Cohen is the largest institutional sharehold", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dsgn/sentiment", "source_name": "TradingKey", "published_at": "2026-06-23T08:11:43", "published_display": "23 Jun 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics Inc (DSGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Design Therapeutics Inc (DSGN), detailing its price momentum, support and resistance levels, and various technical indicators like MACD, RSI, and moving averages. As of June 18, 2026, DSGN has a price momentum score of 9.66 and is sho", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dsgn/technical", "source_name": "TradingKey", "published_at": "2026-06-18T18:09:09", "published_display": "18 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $21", "summary": "Oppenheimer has reiterated its Buy rating for Design Therapeutics (DSGN.US), maintaining a target price of $21. This indicates continued analyst confidence in the company's prospects.", "url": "https://www.moomoo.com/news/post/71536607/oppenheimer-maintains-design-therapeutics-dsgnus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-06-18T08:11:43", "published_display": "18 Jun 2026 08:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics Inc (DSGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Design Therapeutics Inc (DSGN), covering its business segments, regional revenue, and profit contribution. However, the company has not disclosed the relevant data, leading the report to state that this info", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dsgn/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:41", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics Inc (DSGN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Design Therapeutics Inc (DSGN), highlighting its current earnings forecast score, average price target of $12.50, and analyst ratings. Based on 7 analysts, most support a \"Buy\" trend for the stock. The article also touches on past an", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dsgn/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T18:10:41", "published_display": "17 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Wall Street Loves Cadence Design Systems Stock Here", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQT3Ayc2hNOHYxSFJOdnZnUkNqVUx4UGpudWhzTHRFSEhKYTZacTRoaFVsZjRBeG84RnNSOVdSNVZ0ME00ak9udXZ3a0lxanExYVozZE1sNGNpOUVfQUI1Y3RGV0t0czZOU2xwU3BvQ3pNSndPdnVRWlhCajNYajJiZFBuYm9RRjJ6QzNHeDZzMjc2YThFWVREb0hpRUdpSjky?oc=5", "source_name": "Barchart", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cadence Design Systems, Inc. (CDNS) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQeTZBbUNnYnBocUc0SHR6aWFiaU42Yk1idFd1a19vdWdOOGxHcmxqb3FhS212aUxaMWhKWE5HcXdpSXNlT29ET1hweTlTd2ZvVFNQc0U0RXpyWUtycXVzOExONDgyNnQwVkhpRnVQcDhkR2ZzZXVYbFZhTzBuVmFQbjZBOHFQUnc4NEgyMG4tTnRqMWdvUVd2NlRZbGU?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics (DSGN) grants director David Shapiro 30,000 options", "summary": "Design Therapeutics (DSGN) has granted director David Shapiro 30,000 stock options with an exercise price of $10.55 per share, expiring on June 8, 2036. The options will vest in equal monthly installments over 12 months starting from June 9, 2026, and will be fully vested by the ", "url": "https://www.stocktitan.net/sec-filings/DSGN/form-4-design-therapeutics-inc-insider-trading-activity-c1cf25f4e851.html", "source_name": "Stock Titan", "published_at": "2026-06-13T06:10:12", "published_display": "13 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics (DSGN) grants George Simeon 30,000 stock options at $10.55", "summary": "Design Therapeutics (DSGN) director George Simeon was granted 30,000 stock options with an exercise price of $10.55 per share, expiring on June 8, 2036. The options will vest in equal monthly installments over 12 months after June 9, 2026, or fully by the company's next annual st", "url": "https://www.stocktitan.net/sec-filings/DSGN/form-4-design-therapeutics-inc-insider-trading-activity-74a98650a61d.html", "source_name": "Stock Titan", "published_at": "2026-06-12T04:09:35", "published_display": "12 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics (NASDAQ: DSGN) details outcomes of 2026 shareholder meeting votes", "summary": "Design Therapeutics (NASDAQ: DSGN) has released the results of its 2026 Annual Meeting of Stockholders. Shareholders re-elected Simeon George, M.D. as a Class II director and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year endin", "url": "https://www.stocktitan.net/sec-filings/DSGN/8-k-design-therapeutics-inc-reports-material-event-1dd4df8172f9.html", "source_name": "Stock Titan", "published_at": "2026-06-12T03:09:58", "published_display": "12 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Design Therapeutics (DSGN) awarded options on 30,000 shares", "summary": "Design Therapeutics (DSGN) director Justin D. Gover has been granted stock options for 30,000 shares of common stock. These options have an exercise price of $10.55 per share and an expiration date of June 8, 2036. The shares will vest in equal monthly installments over 12 months", "url": "https://www.stocktitan.net/sec-filings/DSGN/form-4-design-therapeutics-inc-insider-trading-activity-9d7c04a8e3b1.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:40:35", "published_display": "11 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics (DSGN) director awarded 30,000 options at $10.55 strike", "summary": "Design Therapeutics (DSGN) director Rodney W. Lappe was granted 30,000 stock options with an exercise price of $10.55 per share, expiring on June 8, 2036. The options will vest in equal monthly installments over 12 months following June 9, 2026, or fully by the company's next ann", "url": "https://www.stocktitan.net/sec-filings/DSGN/form-4-design-therapeutics-inc-insider-trading-activity-493629e352af.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:40:35", "published_display": "11 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Design Therapeutics (DSGN) awarded 30,000 stock options", "summary": "Design Therapeutics (DSGN) director Heather A. Berger was granted 30,000 stock options with an exercise price of $10.55 per share. These options will vest in equal monthly installments over 12 months following June 9, 2026, or fully vest by the company's next annual meeting of st", "url": "https://www.stocktitan.net/sec-filings/DSGN/form-4-design-therapeutics-inc-insider-trading-activity-e114bc617d50.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:40:35", "published_display": "11 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Design Therapeutics, Inc. Insider Trading Activity", "summary": "Design Therapeutics, Inc. director John P. Schmid was granted 30,000 stock options with an exercise price of $10.55 per share, expiring in 2036. These options will vest in equal monthly installments over 12 months starting June 9, 2026, or fully vest by the company's next annual ", "url": "https://www.stocktitan.net/sec-filings/DSGN/form-4-design-therapeutics-inc-insider-trading-activity-25eac415302c.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:40:35", "published_display": "11 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadence Design Systems (CDNS) Stock Moves -1.42%: What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNY2Q4WnJuTEpjREE5Z2pOamNaMEVLZmhodE9JWENZMDFPdEZNamhPZTlsQWN0c0lMeDBNdDh4NHFlcUFQODFzTzh4V1JHQkw3am5fR1RMUUlYUC15ZGZQOTJEcWtlanlJdnljTE1ac0dwalZpQlpjS0J2VUR4MnNTNnlPdm84cGgyNG1lZjdOcEFlbldJcFgxdXdjbkNydUE?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Trending Stock Cadence Design Systems, Inc. (CDNS) a Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQUEkybFZHNV81Y2dHcWJ4aEQyZ3ctTm9HR1M1WVdpZHFaZTZ4dHB4c0xMYXZEU21iY094S1d4Rk9wVWNHd0pCVXRZV1BXcXRpZWtrTEpzMG5VNl80eHozMTNrLTkyRFNvODV4bXV5WTI1U2ZfX3QyM21jQXNtUkM4QzVaSUdtWWEzLVNuTHhfLURySnJXRkxzRDJtbEQwUFZvemRSVw?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/design-therapeutics-participate-2026-jefferies-120000504.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T12:00:00+00:00", "published_display": "28 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Cadence Design Systems (CDNS) Stock Rocketing Higher Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOaFl2djJsdnJlSS16d0R0V2RDYzMxSkNfM0c5MjljSldjeUFLYTBRMVEtRng0VWozZmZ1LWpmaVNuelg3S1JXOEowMXk1ZHpmOUZfOE8xOG1NZXFOXzYxWk9MWFpSUjJjZjZFczJ6OHlxWjRIOGhGVXFEbnRIY3dYUHc3Q1VLR2tORXZadzluRXplYmppSWJOdFdLdjA?oc=5", "source_name": "Market source", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics Shares Jump on Encouraging Friedreich Ataxia Trial Results (DSGN)", "summary": "", "url": "https://finance.yahoo.com/m/4669b54b-3066-329b-9894-f3a853b31801/design-therapeutics-shares.html", "source_name": "InvestorsHub", "published_at": "2026-05-18T14:02:53+00:00", "published_display": "18 May 2026 14:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics' DT-216P2 Shows Clinical Improvements in Friedreich Ataxia Trial; Shares Rise Pre-Bell", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/design-therapeutics-apos-dt-216p2-115332733.html", "source_name": "MT Newswires", "published_at": "2026-05-18T11:53:32+00:00", "published_display": "18 May 2026 11:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/design-therapeutics-announces-four-week-110000362.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T11:00:00+00:00", "published_display": "18 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics stock surges on positive trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOYnVINDBLdkxDUlVDQnRsd3ZkaXcxQWdoMVFhZF9fSzRfVWV5YVBVSU1xVHJMUmNSUnhHVU9uNEdyYTctdXp3WTRLc3VtTVMwM1h0cTRVeWt2ZjdrVktselQwRkZOT0taclNXcVlTMmRwd1pyV3g0QkRSNnVXRkQydTJUWjRBNFZzMEVSZjNuZTRaRHM2bmFiYkxOTk5wUS1jcnZKcFdHOFhvWEc2S2xLSGVGSWRrRE1a?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics, Inc. Stock 12\u2011Month Price Target Raised to $20, Implies 39% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxORXJ1eldTNmVGeFZLbjFzWThpM04tRDZCWFNWX0JPR0prTXhnRWtMUFB4VEZwWDBXNmpiZllrZzBfWE1WZXItVkE1RzVpOXhaRHVkRTlZSVE2WWlfT0VqYTNRZkNINXJNUkVlS2ZxOVBRV1RGN092ZldfaXBpQ19Ld0I0c3pzS0pOUF9WTXpiTExnX01IN2pQYUJzQ1EwV1hPSV9TT0JQcUpYcFg4al9nYkdjWnpHZXpiS0d1Ti16YnFkNi1hUjBsODhlRk5GdXNjVFAzN2lBQjhFRk4t?oc=5", "source_name": "TradingView", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich\u2019s Ataxia on Monday, May 18, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/design-therapeutics-host-investor-webcast-200000077.html", "source_name": "GlobeNewswire", "published_at": "2026-05-17T20:00:00+00:00", "published_display": "17 May 2026 20:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jim Cramer on Design Therapeutics: \u201cPure Spec, Pure Spec\u201d", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQVXMtMFBxYmlkVjN3OG41M2hNMTVhaU81SkpmV25vQWNJa3E1SHBQZU5CZFVJUFREWWh4UF9VUnpnZlYyTzVrSFYwelR4b1FYZlBSM3RzX2NVMTFGT1lTSVVEalRPNXlDdFl6d0kzcDhwa215ZlF3cU90bXBYMTRNNGtxcjZjY3VHb2dBWmhiMjg3bUZIRUZ6bXhzamVQeTlweGc?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cramer: Design Therapeutics Is \u2018Pure Spec,\u2019 Buy This Health Care Stock - BillionToOne (NASDAQ:BLLN), Desi", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNMUdTYmxGYlloV0xUNEZsS01KdDBOc0dGSVBSN1lobjZtUmJnTlZsd2RuQjJDQk8wX1Ffa2RMb0RrM2w2VzZBektMSHdQcDNjbTMzNVhJOVZiY09qZDFxWlhaMk9wT2xnR0s0R2c1V3Y5T3dndkg2dE1wNVFrMEc0YzUzVmdOUTNDZ1VBeXR3ZllnOWZYUzkzWWRhREZRMEVPaTRpbjR1SHctUXQ5S3ZMWVJSbjQyM1AwRjRIR3lBOGRiMmRlampuRktBaWI2bkpES2RHVFQzV1ZrM0hsbjZWcQ?oc=5", "source_name": "Benzinga", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Implied Volatility Surging for Cadence Design Systems Stock Options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPUmkxZkxsRzZuVjdHYTFVcDBRRi1ZaHBzR3VVUzVMY2RYRVE0Z1BfSjB2Ni1ySlYzYnl5eEJfTEVYcWtLbk9CMWJyano4YVpxMFlDT2tCSkRweEt3QzNTTWhIejJuZ29MZXBqRHpzY1BqMjhYaUFvVnRxRzZpNEx2YndxZEQzUjFhY2FQR1VWTlNZbXVsdlR5aFhXUEZZbE00dHBGTmZqQXNBS1U?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Cadence Design Systems (CDNS) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNU01rTS00NE1tdmIzc2dDR3Nmd0lKZXZpalZRb2FfYUxOWFlwODBFRlhNTzVROXJOTjZtMkRpdEJyNnIyYldEQU56X1JGeHFuYXZRUW0tbk1BR3lOdWtrMDliNHhSMVB2SnZDSkhCYS15aW9Oel9zY3p0X0RDTkoxcjR5Q2tqcDdjc1VHSkZmWUQ0M3BsNmQyLVpzamI?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadence Design Systems (CDNS) Stock Is Up, What You Need To Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPMXoyOUgxaEZyNDlGRFlmRXFXdE84YnhlakVLekQ0UHhfN1FqMlp4TC0xQVExclktTEVBblBISHJxTFdoMjVxclFNSnh1NXVuLWl4OF9XVjhxLS1KVHo0TzE3UmdWMEZGMHJ1amowbkNDeTE4UFhJcHljT09XVjZfMGhnUU9OXzk5YzNOZVN3ZmptYjhlN3FRSDZ6aGcyTjg?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadence Design Systems (CDNS) Stock Drops Despite Market Gains: Important Facts to Note", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPUDZvWFA0S3R2ZW82eDg4bUJtUkN5c1F4YkVpNDFmM2h5UTVjY3d1Y1VMblZzOHRNa05OeGpGdjBrNGRsb3hDRldRdmdfQlJlZjd3SG1qR2M2TjN3a2FjdVhtYlhPQnpEV25vZFdzWkVGMU9sYWFFVVZNZDVYYllHM1E1ek13LVhNNmY1dF9PeFRkUWxKaWhaLXdJb3pNRDA?oc=5", "source_name": "Market source", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "RBC Capital maintains Design Therapeutics stock rating with $5 target By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNVVRtdFc1RWYzMzN0dUo2bG5lOElYZVNWMFlUWmJjNlI2dnJoSU1SNTdvdUtoZFhlaWVpQlZuT1pYYTZmY1k0MlI0Ymk1c3hlZFZ1eWY0WlhlM016VTVPOTFwcGkyUktnS3ZJd2xkRW1EemVVZ2c3UmozR0JLWkpqVm1DcV9ZXy1oVnpEanVEVFJsU05vcWpVaXdkbUdCa1htQmwxX01rRVl6aDJRdk5nNTdMQzFlV1VDOFNjOTBoN3RfcTlRdnc?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2025-06-04T07:00:00+00:00", "published_display": "04 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics (DSGN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBkLUxLeE5IQm43MmFCUWtvVWR2bXpGREZ5TDNsdjNLbk50WEppbjdGZG5OVzk4UFhXN3dqQ3d4V0NtRVc2anR4ckRHT3lPV0ZKVG9j?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:01:24+00:00", "published_display": "25 Apr 2025 00:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Myotonic Dystrophy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 \u2013 DelveInsight | Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Bioscien", "summary": "The Myotonic Dystrophy market is projected to reach approximately USD 89 million in 2023 and grow at an 18.4% CAGR through 2036, driven by increased disease awareness, genetic research advancements, and a robust clinical pipeline. Several companies, including Avidity Biosciences ", "url": "https://www.barchart.com/story/news/3186311/myotonic-dystrophy-market-expected-to-experience-accelerated-growth-and-market-evolution-by-2036-delveinsight-design-therapeutics-enzerna-juvena-therapeutics-dyne-therapeutics-avidity-bioscien", "source_name": "Barchart.com", "published_at": "2026-07-08T14:10:50", "published_display": "08 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Design Therapeutics, Inc. (DSGN)", "summary": "This article examines the historical performance of investing $1,000 in Design Therapeutics, Inc. (DSGN) over various periods, showing substantial gains in the last year but losses over longer terms. It also provides a detailed overview of the company, a clinical-stage biotechnol", "url": "https://www.stocktitan.net/tools/stock-return-calculator/DSGN", "source_name": "Stock Titan", "published_at": "2026-07-04T12:40:30", "published_display": "04 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Design Therapeutics, Inc. \u2013 NASDAQ:DSGN", "summary": "This article displays the \"Price to sales forward\" financial metric for Design Therapeutics, Inc. (NASDAQ: DSGN). The content includes the company's stock symbol, market, and a brief mention of the financial data period, value, and change.", "url": "https://www.tradingview.com/symbols/NASDAQ-DSGN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T05:11:30", "published_display": "03 Jul 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Design Therapeutics, Inc. \u2013 NASDAQ:DSGN", "summary": "This page from TradingView displays financial information for Design Therapeutics, Inc. (NASDAQ: DSGN), specifically focusing on its forward price-to-earnings ratio. The content indicates that the market was closed at the time of access, with no trades occurring. The page also li", "url": "https://www.tradingview.com/symbols/NASDAQ-DSGN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T03:09:11", "published_display": "03 Jul 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics (Nasdaq:DSGN) - Stock Analysis", "summary": "This article provides a stock analysis of Design Therapeutics (DSGN), highlighting its current market performance, risk factors, and pipeline developments. The company, a clinical-stage biopharmaceutical firm focusing on genetic diseases, shows significant stock growth over the p", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dsgn/design-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-07-01T12:10:56", "published_display": "01 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Design Therapeutics stock rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQcU1JaXAwekYtT2dsbUo3blRzdUtIa0xGTGFuNzBGdXhfXzhrR3phTHZnMW1jdFNHMWtfTGJGVzA2dXhyLV9WcC11anlvX0VCZi1ZeFFrZGdheEdrV0RLdVhTbUpydjU2bWoxdzlFMlRIY3duOWRSUTlvbkIyZ2p3XzF3Q0xscm9lcWRhc2lkT0Z3OWRrWDVLa0NLYmExNko5VHJNRGIzaGhxaHZISWotODF3cUt2ZDhOdXN4dFpR?oc=5", "source_name": "Investing.com", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics begins dosing DM1 drug in phase 1 trial By Investing.com", "summary": "Design Therapeutics (NASDAQ:DSGN) has initiated patient dosing for its DT-818 drug in a Phase 1 clinical trial for adults with myotonic dystrophy type-1, leading to a 6.7% surge in its stock. The company anticipates reporting data from this trial in 2027 and continues to advance ", "url": "https://ca.investing.com/news/stock-market-news/design-therapeutics-begins-dosing-dm1-drug-in-phase-1-trial-93CH-4713737", "source_name": "Investing.com Canada", "published_at": "2026-06-30T23:10:16", "published_display": "30 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics begins DM1 trial for DT-818, aims at genetic cause", "summary": "Design Therapeutics (Nasdaq: DSGN) has initiated patient dosing for its Phase 1 multiple-ascending dose (MAD) trial of DT-818, a GeneTAC small molecule, for adults with myotonic dystrophy type-1 (DM1). DT-818 is designed to address the underlying genetic cause of DM1 by selective", "url": "https://www.stocktitan.net/news/DSGN/design-therapeutics-announces-initiation-of-patient-dosing-in-phase-uqdjp75me0ja.html", "source_name": "Stock Titan", "published_at": "2026-06-30T23:10:16", "published_display": "30 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics begins dosing DM1 drug in phase 1 trial", "summary": "Design Therapeutics (NASDAQ:DSGN) has commenced patient dosing in a Phase 1 clinical trial for DT-818, a potential treatment for myotonic dystrophy type-1 (DM1). The company's stock surged on the news, having already seen significant gains over the past year. DT-818 is designed t", "url": "https://www.investing.com/news/company-news/design-therapeutics-begins-dosing-dm1-drug-in-phase-1-trial-93CH-4767732", "source_name": "Investing.com", "published_at": "2026-06-30T12:41:11", "published_display": "30 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 79, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics stock rises on Phase 1 trial dosing start By Investing.com", "summary": "Design Therapeutics Inc. (NASDAQ:DSGN) shares rose in premarket trading after the company announced the initiation of patient dosing in its Phase 1 trial for DT-818. This GeneTAC small molecule aims to treat myotonic dystrophy type-1 (DM1) by targeting the underlying genetic caus", "url": "https://m.au.investing.com/news/stock-market-news/design-therapeutics-stock-rises-on-phase-1-trial-dosing-start-93CH-4511350?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-30T12:41:11", "published_display": "30 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1", "summary": "Design Therapeutics has initiated patient dosing for its Phase 1 multiple-ascending dose (MAD) clinical trial of DT-818, a GeneTAC\u00ae small molecule for Myotonic Dystrophy Type-1 (DM1). DT-818 is designed to address the genetic cause of DM1 by selectively reducing the transcription", "url": "https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/design-therapeutics-announces-initiation-of-patient-dosing-in-phase-1-multiple-ascending-dose-trial-of-dt-818-for-myotonic-dystrophy-type-1/2375725", "source_name": "The Manila Times", "published_at": "2026-06-30T11:41:11", "published_display": "30 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics spikes as RBC upgrades on an eventful 2026", "summary": "Design Therapeutics (NASDAQ:DSGN) saw its shares rise after RBC Capital upgraded the stock, citing upcoming catalysts and a potentially \"eventful\" 2026. The upgrade reflects optimism about the company's future prospects and clinical developments.", "url": "http://www.msn.com/en-us/money/savingandinvesting/design-therapeutics-spikes-as-rbc-upgrades-on-an-eventful-2026/ar-AA1QPGsJ?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-30T11:09:52", "published_display": "30 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics, Inc.(NasdaqGS:DSGN) added to Russell Small Cap Comp Growth Benchmark", "summary": "Design Therapeutics, Inc. (DSGN) has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion is among several recent updates for the company within the Russell indices, including additions to the Russell 2500 Growth Benchmark and Russell Microcap Growth Benchmar", "url": "https://www.marketscreener.com/news/design-therapeutics-inc-nasdaqgs-dsgn-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc8bf424", "source_name": "marketscreener.com", "published_at": "2026-06-29T21:39:45", "published_display": "29 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics, Inc.(NasdaqGS: DSGN) dropped from Russell 2000 Value Benchmark", "summary": "Design Therapeutics, Inc. (NasdaqGS: DSGN) has been removed from the Russell 2000 Value Benchmark, as announced on June 29, 2026. This news comes alongside several other Russell index adjustments for the company, including being added to the Russell Small Cap Comp Growth, Russell", "url": "https://www.marketscreener.com/news/design-therapeutics-inc-nasdaqgs-dsgn-dropped-from-russell-2000-value-benchmark-ce7f5fdfd88cf722", "source_name": "marketscreener.com", "published_at": "2026-06-29T15:39:45", "published_display": "29 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 3000E Growth Benchmark", "summary": "Design Therapeutics, Inc. (NasdaqGS: DSGN) has been added to the Russell 3000E Growth Benchmark. The company specializes in developing GeneTACT molecules\u2014small-molecule gene-targeted chimera therapeutic candidates designed for diseases caused by inherited nucleotide repeat expans", "url": "https://www.marketscreener.com/news/design-therapeutics-inc-nasdaqgs-dsgn-added-to-russell-3000e-growth-benchmark-ce7f5fdedf88f325", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:10:48", "published_display": "29 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely", "summary": "Design Therapeutics (NASDAQ:DSGN), a loss-making company, saw its share price soar by 274% over the last year. Despite an increase in cash burn to US$54 million, the company maintains a robust cash runway of 4.1 years based on its US$223 million cash reserves. Analysts believe De", "url": "https://www.sahmcapital.com/news/content/were-hopeful-that-design-therapeutics-nasdaqdsgn-will-use-its-cash-wisely-2026-06-27", "source_name": "Sahm", "published_at": "2026-06-27T10:40:21", "published_display": "27 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics, Inc. Actuals & Estimates (NASDAQ:DSGN)", "summary": "This article provides an overview of Design Therapeutics, Inc. (DSGN) stock performance, financial estimates, and analyst forecasts. It includes details on the current stock price, volatility, market capitalization, historical highs and lows, and upcoming earnings reports, along ", "url": "https://www.tradingview.com/symbols/NASDAQ-DSGN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T05:10:05", "published_display": "27 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DSGN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an outlook on Design Therapeutics, Inc. (DSGN) stock, including analyst price targets, historical performance, and financial data. Analysts predict a max estimate of $22.00 and a min estimate of $20.00 for DSGN. The company's stock has shown significant grow", "url": "https://www.tradingview.com/symbols/NASDAQ-DSGN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T08:41:54", "published_display": "26 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics Inc (DSGN) Institutional Confidence", "summary": "Design Therapeutics Inc (DSGN) has an institutional shareholding score of 5.00, ranking 132nd in the Biotechnology & Medical Research industry, with institutional shareholding at 61.89%, a decrease of 8.26% quarter-over-quarter. Steven Cohen is the largest institutional sharehold", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dsgn/sentiment", "source_name": "TradingKey", "published_at": "2026-06-23T08:11:43", "published_display": "23 Jun 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics Inc (DSGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Design Therapeutics Inc (DSGN), detailing its price momentum, support and resistance levels, and various technical indicators like MACD, RSI, and moving averages. As of June 18, 2026, DSGN has a price momentum score of 9.66 and is sho", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dsgn/technical", "source_name": "TradingKey", "published_at": "2026-06-18T18:09:09", "published_display": "18 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $21", "summary": "Oppenheimer has reiterated its Buy rating for Design Therapeutics (DSGN.US), maintaining a target price of $21. This indicates continued analyst confidence in the company's prospects.", "url": "https://www.moomoo.com/news/post/71536607/oppenheimer-maintains-design-therapeutics-dsgnus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-06-18T08:11:43", "published_display": "18 Jun 2026 08:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics Inc (DSGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Design Therapeutics Inc (DSGN), covering its business segments, regional revenue, and profit contribution. However, the company has not disclosed the relevant data, leading the report to state that this info", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dsgn/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:41", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics Inc (DSGN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Design Therapeutics Inc (DSGN), highlighting its current earnings forecast score, average price target of $12.50, and analyst ratings. Based on 7 analysts, most support a \"Buy\" trend for the stock. The article also touches on past an", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-dsgn/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T18:10:41", "published_display": "17 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Wall Street Loves Cadence Design Systems Stock Here", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQT3Ayc2hNOHYxSFJOdnZnUkNqVUx4UGpudWhzTHRFSEhKYTZacTRoaFVsZjRBeG84RnNSOVdSNVZ0ME00ak9udXZ3a0lxanExYVozZE1sNGNpOUVfQUI1Y3RGV0t0czZOU2xwU3BvQ3pNSndPdnVRWlhCajNYajJiZFBuYm9RRjJ6QzNHeDZzMjc2YThFWVREb0hpRUdpSjky?oc=5", "source_name": "Barchart", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cadence Design Systems, Inc. (CDNS) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQeTZBbUNnYnBocUc0SHR6aWFiaU42Yk1idFd1a19vdWdOOGxHcmxqb3FhS212aUxaMWhKWE5HcXdpSXNlT29ET1hweTlTd2ZvVFNQc0U0RXpyWUtycXVzOExONDgyNnQwVkhpRnVQcDhkR2ZzZXVYbFZhTzBuVmFQbjZBOHFQUnc4NEgyMG4tTnRqMWdvUVd2NlRZbGU?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics (DSGN) grants director David Shapiro 30,000 options", "summary": "Design Therapeutics (DSGN) has granted director David Shapiro 30,000 stock options with an exercise price of $10.55 per share, expiring on June 8, 2036. The options will vest in equal monthly installments over 12 months starting from June 9, 2026, and will be fully vested by the ", "url": "https://www.stocktitan.net/sec-filings/DSGN/form-4-design-therapeutics-inc-insider-trading-activity-c1cf25f4e851.html", "source_name": "Stock Titan", "published_at": "2026-06-13T06:10:12", "published_display": "13 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics (DSGN) grants George Simeon 30,000 stock options at $10.55", "summary": "Design Therapeutics (DSGN) director George Simeon was granted 30,000 stock options with an exercise price of $10.55 per share, expiring on June 8, 2036. The options will vest in equal monthly installments over 12 months after June 9, 2026, or fully by the company's next annual st", "url": "https://www.stocktitan.net/sec-filings/DSGN/form-4-design-therapeutics-inc-insider-trading-activity-74a98650a61d.html", "source_name": "Stock Titan", "published_at": "2026-06-12T04:09:35", "published_display": "12 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics (NASDAQ: DSGN) details outcomes of 2026 shareholder meeting votes", "summary": "Design Therapeutics (NASDAQ: DSGN) has released the results of its 2026 Annual Meeting of Stockholders. Shareholders re-elected Simeon George, M.D. as a Class II director and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year endin", "url": "https://www.stocktitan.net/sec-filings/DSGN/8-k-design-therapeutics-inc-reports-material-event-1dd4df8172f9.html", "source_name": "Stock Titan", "published_at": "2026-06-12T03:09:58", "published_display": "12 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Design Therapeutics (DSGN) awarded options on 30,000 shares", "summary": "Design Therapeutics (DSGN) director Justin D. Gover has been granted stock options for 30,000 shares of common stock. These options have an exercise price of $10.55 per share and an expiration date of June 8, 2036. The shares will vest in equal monthly installments over 12 months", "url": "https://www.stocktitan.net/sec-filings/DSGN/form-4-design-therapeutics-inc-insider-trading-activity-9d7c04a8e3b1.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:40:35", "published_display": "11 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics (DSGN) director awarded 30,000 options at $10.55 strike", "summary": "Design Therapeutics (DSGN) director Rodney W. Lappe was granted 30,000 stock options with an exercise price of $10.55 per share, expiring on June 8, 2036. The options will vest in equal monthly installments over 12 months following June 9, 2026, or fully by the company's next ann", "url": "https://www.stocktitan.net/sec-filings/DSGN/form-4-design-therapeutics-inc-insider-trading-activity-493629e352af.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:40:35", "published_display": "11 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Design Therapeutics (DSGN) awarded 30,000 stock options", "summary": "Design Therapeutics (DSGN) director Heather A. Berger was granted 30,000 stock options with an exercise price of $10.55 per share. These options will vest in equal monthly installments over 12 months following June 9, 2026, or fully vest by the company's next annual meeting of st", "url": "https://www.stocktitan.net/sec-filings/DSGN/form-4-design-therapeutics-inc-insider-trading-activity-e114bc617d50.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:40:35", "published_display": "11 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Design Therapeutics, Inc. Insider Trading Activity", "summary": "Design Therapeutics, Inc. director John P. Schmid was granted 30,000 stock options with an exercise price of $10.55 per share, expiring in 2036. These options will vest in equal monthly installments over 12 months starting June 9, 2026, or fully vest by the company's next annual ", "url": "https://www.stocktitan.net/sec-filings/DSGN/form-4-design-therapeutics-inc-insider-trading-activity-25eac415302c.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:40:35", "published_display": "11 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadence Design Systems (CDNS) Stock Moves -1.42%: What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNY2Q4WnJuTEpjREE5Z2pOamNaMEVLZmhodE9JWENZMDFPdEZNamhPZTlsQWN0c0lMeDBNdDh4NHFlcUFQODFzTzh4V1JHQkw3am5fR1RMUUlYUC15ZGZQOTJEcWtlanlJdnljTE1ac0dwalZpQlpjS0J2VUR4MnNTNnlPdm84cGgyNG1lZjdOcEFlbldJcFgxdXdjbkNydUE?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Trending Stock Cadence Design Systems, Inc. (CDNS) a Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQUEkybFZHNV81Y2dHcWJ4aEQyZ3ctTm9HR1M1WVdpZHFaZTZ4dHB4c0xMYXZEU21iY094S1d4Rk9wVWNHd0pCVXRZV1BXcXRpZWtrTEpzMG5VNl80eHozMTNrLTkyRFNvODV4bXV5WTI1U2ZfX3QyM21jQXNtUkM4QzVaSUdtWWEzLVNuTHhfLURySnJXRkxzRDJtbEQwUFZvemRSVw?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/design-therapeutics-participate-2026-jefferies-120000504.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T12:00:00+00:00", "published_display": "28 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Cadence Design Systems (CDNS) Stock Rocketing Higher Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOaFl2djJsdnJlSS16d0R0V2RDYzMxSkNfM0c5MjljSldjeUFLYTBRMVEtRng0VWozZmZ1LWpmaVNuelg3S1JXOEowMXk1ZHpmOUZfOE8xOG1NZXFOXzYxWk9MWFpSUjJjZjZFczJ6OHlxWjRIOGhGVXFEbnRIY3dYUHc3Q1VLR2tORXZadzluRXplYmppSWJOdFdLdjA?oc=5", "source_name": "Market source", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics Shares Jump on Encouraging Friedreich Ataxia Trial Results (DSGN)", "summary": "", "url": "https://finance.yahoo.com/m/4669b54b-3066-329b-9894-f3a853b31801/design-therapeutics-shares.html", "source_name": "InvestorsHub", "published_at": "2026-05-18T14:02:53+00:00", "published_display": "18 May 2026 14:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics' DT-216P2 Shows Clinical Improvements in Friedreich Ataxia Trial; Shares Rise Pre-Bell", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/design-therapeutics-apos-dt-216p2-115332733.html", "source_name": "MT Newswires", "published_at": "2026-05-18T11:53:32+00:00", "published_display": "18 May 2026 11:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/design-therapeutics-announces-four-week-110000362.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T11:00:00+00:00", "published_display": "18 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics stock surges on positive trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOYnVINDBLdkxDUlVDQnRsd3ZkaXcxQWdoMVFhZF9fSzRfVWV5YVBVSU1xVHJMUmNSUnhHVU9uNEdyYTctdXp3WTRLc3VtTVMwM1h0cTRVeWt2ZjdrVktselQwRkZOT0taclNXcVlTMmRwd1pyV3g0QkRSNnVXRkQydTJUWjRBNFZzMEVSZjNuZTRaRHM2bmFiYkxOTk5wUS1jcnZKcFdHOFhvWEc2S2xLSGVGSWRrRE1a?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics, Inc. Stock 12\u2011Month Price Target Raised to $20, Implies 39% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxORXJ1eldTNmVGeFZLbjFzWThpM04tRDZCWFNWX0JPR0prTXhnRWtMUFB4VEZwWDBXNmpiZllrZzBfWE1WZXItVkE1RzVpOXhaRHVkRTlZSVE2WWlfT0VqYTNRZkNINXJNUkVlS2ZxOVBRV1RGN092ZldfaXBpQ19Ld0I0c3pzS0pOUF9WTXpiTExnX01IN2pQYUJzQ1EwV1hPSV9TT0JQcUpYcFg4al9nYkdjWnpHZXpiS0d1Ti16YnFkNi1hUjBsODhlRk5GdXNjVFAzN2lBQjhFRk4t?oc=5", "source_name": "TradingView", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich\u2019s Ataxia on Monday, May 18, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/design-therapeutics-host-investor-webcast-200000077.html", "source_name": "GlobeNewswire", "published_at": "2026-05-17T20:00:00+00:00", "published_display": "17 May 2026 20:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jim Cramer on Design Therapeutics: \u201cPure Spec, Pure Spec\u201d", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQVXMtMFBxYmlkVjN3OG41M2hNMTVhaU81SkpmV25vQWNJa3E1SHBQZU5CZFVJUFREWWh4UF9VUnpnZlYyTzVrSFYwelR4b1FYZlBSM3RzX2NVMTFGT1lTSVVEalRPNXlDdFl6d0kzcDhwa215ZlF3cU90bXBYMTRNNGtxcjZjY3VHb2dBWmhiMjg3bUZIRUZ6bXhzamVQeTlweGc?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cramer: Design Therapeutics Is \u2018Pure Spec,\u2019 Buy This Health Care Stock - BillionToOne (NASDAQ:BLLN), Desi", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNMUdTYmxGYlloV0xUNEZsS01KdDBOc0dGSVBSN1lobjZtUmJnTlZsd2RuQjJDQk8wX1Ffa2RMb0RrM2w2VzZBektMSHdQcDNjbTMzNVhJOVZiY09qZDFxWlhaMk9wT2xnR0s0R2c1V3Y5T3dndkg2dE1wNVFrMEc0YzUzVmdOUTNDZ1VBeXR3ZllnOWZYUzkzWWRhREZRMEVPaTRpbjR1SHctUXQ5S3ZMWVJSbjQyM1AwRjRIR3lBOGRiMmRlampuRktBaWI2bkpES2RHVFQzV1ZrM0hsbjZWcQ?oc=5", "source_name": "Benzinga", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Implied Volatility Surging for Cadence Design Systems Stock Options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPUmkxZkxsRzZuVjdHYTFVcDBRRi1ZaHBzR3VVUzVMY2RYRVE0Z1BfSjB2Ni1ySlYzYnl5eEJfTEVYcWtLbk9CMWJyano4YVpxMFlDT2tCSkRweEt3QzNTTWhIejJuZ29MZXBqRHpzY1BqMjhYaUFvVnRxRzZpNEx2YndxZEQzUjFhY2FQR1VWTlNZbXVsdlR5aFhXUEZZbE00dHBGTmZqQXNBS1U?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Cadence Design Systems (CDNS) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNU01rTS00NE1tdmIzc2dDR3Nmd0lKZXZpalZRb2FfYUxOWFlwODBFRlhNTzVROXJOTjZtMkRpdEJyNnIyYldEQU56X1JGeHFuYXZRUW0tbk1BR3lOdWtrMDliNHhSMVB2SnZDSkhCYS15aW9Oel9zY3p0X0RDTkoxcjR5Q2tqcDdjc1VHSkZmWUQ0M3BsNmQyLVpzamI?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadence Design Systems (CDNS) Stock Is Up, What You Need To Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPMXoyOUgxaEZyNDlGRFlmRXFXdE84YnhlakVLekQ0UHhfN1FqMlp4TC0xQVExclktTEVBblBISHJxTFdoMjVxclFNSnh1NXVuLWl4OF9XVjhxLS1KVHo0TzE3UmdWMEZGMHJ1amowbkNDeTE4UFhJcHljT09XVjZfMGhnUU9OXzk5YzNOZVN3ZmptYjhlN3FRSDZ6aGcyTjg?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadence Design Systems (CDNS) Stock Drops Despite Market Gains: Important Facts to Note", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPUDZvWFA0S3R2ZW82eDg4bUJtUkN5c1F4YkVpNDFmM2h5UTVjY3d1Y1VMblZzOHRNa05OeGpGdjBrNGRsb3hDRldRdmdfQlJlZjd3SG1qR2M2TjN3a2FjdVhtYlhPQnpEV25vZFdzWkVGMU9sYWFFVVZNZDVYYllHM1E1ek13LVhNNmY1dF9PeFRkUWxKaWhaLXdJb3pNRDA?oc=5", "source_name": "Market source", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital maintains Design Therapeutics stock rating with $5 target By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNVVRtdFc1RWYzMzN0dUo2bG5lOElYZVNWMFlUWmJjNlI2dnJoSU1SNTdvdUtoZFhlaWVpQlZuT1pYYTZmY1k0MlI0Ymk1c3hlZFZ1eWY0WlhlM016VTVPOTFwcGkyUktnS3ZJd2xkRW1EemVVZ2c3UmozR0JLWkpqVm1DcV9ZXy1oVnpEanVEVFJsU05vcWpVaXdkbUdCa1htQmwxX01rRVl6aDJRdk5nNTdMQzFlV1VDOFNjOTBoN3RfcTlRdnc?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2025-06-04T07:00:00+00:00", "published_display": "04 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Design Therapeutics (DSGN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBkLUxLeE5IQm43MmFCUWtvVWR2bXpGREZ5TDNsdjNLbk50WEppbjdGZG5OVzk4UFhXN3dqQ3d4V0NtRVc2anR4ckRHT3lPV0ZKVG9j?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:01:24+00:00", "published_display": "25 Apr 2025 00:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 96, "total_relevant": 58, "sentiment_summary": {"positive": 24, "negative": 1, "neutral": 33, "score": 59, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 20.35, "count": 37}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 24, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 15.19, "latest_week": "2026-07-10", "one_week_move": -2.9, "four_week_move": 38.5, "twelve_week_move": 15.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.123729, "market_dynamics_buy_signal": false, "relative_strength": 43.429856, "fair_value_gap": 164.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 55.8703, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.9% over one week, +38.5% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 70, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "Stock Titan", "count": 10}, {"label": "TradingView", "count": 6}, {"label": "TradingKey", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "marketscreener.com", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 37}, {"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 5}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-2.9% over one week, +38.5% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Myotonic Dystrophy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 \u2013 DelveInsight | Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Bioscien"}], "updated_at": "2026-07-16T10:53:05.395726+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}